Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalop...
Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in ...
Wong Yu Jun, Singapore, Singapore
Bayhealth Medical Center- Dover Family Physicians and GI Consultants Office, Dover, Delaware, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
Dr. Bofill Clinic, Girona, Spain
Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, Uttar Pradesh, India
Department of Critical Care Medicine, SGPGIMS, Lucknow, UP, India
Mayo Clinic in Florida, Jacksonville, Florida, United States
Mayo Clinic in Florida, Jacksonville, Florida, United States
Sherief Abd-Elsalam, Tanta, Egypt
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.